Novavax posts higher-than-expected revenue, says prepared to further cut costs

[cafead]

via COVID-19 vaccine maker Novavax (NVAX.O) on Thursday reported higher-than-expected revenue for the third quarter, boosted by U.S. government grants to help cover the expense of clinical trials, and said it was prepared to further cut costs next year.

article source